Latest News

The phase 3 LUNA study showed that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduced perimenstrual migraine days among patients with menstrual migraine compared with placebo.

The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.

The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.

A newly launched global phase 3 trial will compare once-daily trientine with D-penicillamine as first-line treatment for patients with Wilson disease, a rare genetic disorder.

Updated phase 1/2 POLARIS data showed sustained reductions in seizure frequency and progressive gains in cognitive and adaptive measures following a single administration of investigational ETX101 in children with SCN1A+ Dravet syndrome.

New real-world data showed that daily corticosteroid therapy preserved motor function longer in patients with Duchenne muscular dystrophy compared with an intermittent dosing regimen.

The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to Alzheimer risk.

A new study suggests excessive daytime sleepiness in obstructive sleep apnea may be associated with cognitive impairment and altered brain network connectivity in the middle frontal gyrus and inferior parietal lobule.

Delpacibart etedesiran did not demonstrate statistically significant improvement in myotonic dystrophy type 1 in the phase 3 HARBOR study, despite reported signals of clinical activity across secondary and exploratory measures.

A randomized clinical trial found that intravenous tirofiban plus aspirin did not significantly reduce early neurological deterioration or new stroke compared with aspirin alone i patients with branch atheromatous disease–related stroke.

A recent study of Brazilian adolescents showed a high prevalence of excessive daytime sleepiness, with severe depressive symptoms and smartphone addiction emerging as the strongest independent risk factors.

Here's some of what is coming soon to NeurologyLive® this week.

Newly published KINECT-PRO data showed that valbenazine boosted quality of life and function while reducing movement severity, with remission for many patients with tardive dyskinesia by 24 weeks.